Drug Profile

STRX 210

Alternative Names: AAV-based NPC1 therapy- Sarepta Therapeutics/StrideBio; STRX-210

Latest Information Update: 06 Sep 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

27 Aug 2021 Preclinical trials in Niemann-Pick disease type C in USA (Parenteral) (StrideBio pipeline, August 2021)
14 Nov 2019 StrideBio and Sarepta Therapeutics agree to co-develop Niemann-Pick disease gene therapies
14 Nov 2019 Early research in Niemann-Pick disease type C in USA (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com